T
Power Law company profile
Tessera Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2018 Unicorn
Global footprint
Where Tessera Therapeutics has talent and traffic
AI talent share
2.3%
of workforce is AI talent
(5 of 216 staff)
(5 of 216 staff)
Core AI52.31%
Other AI00%
Non-AI workforce21197.69%
Web traffic by country
8.6K
monthly visits
across markets
across markets
🇺🇸 United States74.4%
🇬🇧 United Kingdom12.8%
🇮🇳 India3.5%
🇵🇭 Philippines3.5%
🇯🇵 Japan2.3%
Patent intelligence
$354k patent portfolio · 6 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$354k
0.02% of valuation · 5726.8× smaller than top peer Ablynx ($2B)
6 active patent families
Where Tessera Therapeutics innovates
Molecular biologyCell biologyNanoparticlePharmaceutical drugGenome
Below peer median on Legal, Strategic, Market, Economic, Technology
Quality vs same-sector peers
Tessera Therapeutics on the five Patsnap quality dimensions
Tessera Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Tessera Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Tessera Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Tessera Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.